Metformin Clinical Trial
Official title:
Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
About 75% of CNS malignant tumors are classified as gliomas and the IDH-wildtype glioblastoma (GBM) represents the most aggressive form among CNS malignancies. This is a nationwide single-center phase II drug clinical trial with an approximate duration of 32 months. The clinical trial will be single-arm to evaluate the biological activity and effects of metformin in combination with TMZ in patients with GBM.
About 75% of CNS malignant tumors are classified as gliomas, tumors of neuroectodermal origin arising from glial cells or glial cell precursors. The World Health Organization classification distinguishes gliomas into low-grade gliomas (low-grade gliomas, grade I and II) and high-grade gliomas (high-grade gliomas, grade III and IV). IDH-wildtype glioblastoma (GBM) represents the most aggressive form among CNS malignancies. Over the past century, numerous epidemiological and experimental observations have reported a preventive and beneficial antitumor effect of metformin, which has suggested the possibility of using it as adjunctive therapy in many cancer subtypes, including GBM. The aim of this study is to evaluate the effect of Metformin as adjuvant therapy to TMZ in the treatment of patients with GBM. Patients will start with a Metformin dose of 1 g/day orally in two administrations (500 mg tablets) during the first two weeks of treatment, increasing to 2 g/day in two 1 g tablets thereafter. The approximate total duration of the study is 32 months, and 25 patients will be enrolled ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05052918 -
The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes
|
N/A | |
Recruiting |
NCT05469659 -
Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)
|
Phase 2 | |
Completed |
NCT00767351 -
Variation in Serum Levels of Metformin in Patients With Reduced Renal Function
|
||
Recruiting |
NCT06126029 -
Effect of Metformin as Add-on Therapy to Ibuprofen on Disease Activity in Knee Osteoarthritis Patients.
|
Phase 2 | |
Enrolling by invitation |
NCT05900284 -
Safety and Feasibility of Metformin for Sepsis Induced AKI
|
Phase 2 | |
Enrolling by invitation |
NCT06125587 -
Chiglitazar/Metformin in Non-obese Women With PCOS
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05013112 -
Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)
|
N/A | |
Recruiting |
NCT03525028 -
A Clinical Trial of Metformin to Decrease Glucocorticoids Side Effects in Patients With Autoimmune Uveitis
|
N/A | |
Recruiting |
NCT05680805 -
Metabolic Responses of Metformin and Genetic Polymorphisms of SLC22A1 Gene in PCOS
|
Phase 4 | |
Not yet recruiting |
NCT05532813 -
Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
|
Phase 3 | |
Recruiting |
NCT06325956 -
PCOS Immune Function Predicts Metformin Efficacy
|
N/A | |
Recruiting |
NCT06325969 -
PCOS Patients Immune Status Evaluation
|
||
Completed |
NCT03335423 -
Inter- and Intra-individual Variations in Metformin Pharmacokinetics - The Importance of Genes and Drug Interactions
|
Phase 1 | |
Recruiting |
NCT04477590 -
Interactions of Medicine and Exercise With Meal Timing
|
N/A | |
Not yet recruiting |
NCT06459310 -
Pilot Study on Evaluating the Geroprotective Effect of Metformin
|
Phase 2 | |
Not yet recruiting |
NCT05412056 -
Metformin to Prevent Preterm Birth in Twin Pregnancy
|
Phase 2/Phase 3 | |
Terminated |
NCT01756105 -
Efficacy of Metformin in Achieving Glycaemia Goals as Recommended for the Treatment of Gestational Diabetes in Non Obese Women
|
Phase 2 | |
Completed |
NCT04377451 -
Metformin in Dengue With Obesity
|
Phase 1/Phase 2 | |
Completed |
NCT03618472 -
Comparison of the Effectiveness Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells
|
N/A | |
Recruiting |
NCT04581447 -
Extending Time Without Diabetes After Bariatric Surgery: a Trial Comparing the Metformin Addition or Not to Standard Care
|
Phase 3 |